Poster

Modelling neurodegeneration using a human isogenic system: A next generation approach to study frontotemporal dementia and amyotrophic lateral sclerosis

This poster was presented by bit.bio at AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and the ISSCR Annual Meeting 2023. The poster shows FTD and ALS disease-related phenotypic data for ioGlutamatergic Neurons disease model cells carrying a mutation in MAPT or TDP-43 (TARDBP).
Modelling neurodegeneration using a human isogenic system: A next generation approach to study frontotemporal dementia and amyotrophic lateral sclerosis

Dr Tony Oosterveen, et al.

bit.bio & Charles River Laboratories

2023

Modelling neurodegeneration using a human isogenic system: A next generation approach to study frontotemporal dementia and amyotrophic lateral sclerosis
This poster was presented by bit.bio at AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and the ISSCR Annual Meeting 2023. The poster shows FTD and ALS disease-related phenotypic data for ioGlutamatergic Neurons disease model cells carrying a mutation in MAPT or TDP-43 (TARDBP).
Modelling neurodegeneration using a human isogenic system: A next generation approach to study frontotemporal dementia and amyotrophic lateral sclerosis

Dr Tony Oosterveen, et al.

bit.bio & Charles River Laboratories

2023

We have developed human iPSC-derived disease models for frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) to improve screening specificity and accelerate early drug discovery for these neurodegenerative disorders. Using CRISPR/Cas9 gene editing, we introduced the disease-relevant mutation M337V in the TDP-43 (TARDBP) gene, or the mutation P301S or N279K in the MAPT gene, of wild type ioGlutamatergic Neurons (isogenic control). Disease-related phenotypic differences between the disease model cells and the isogenic control were detected by microelectrode array (MEA) analysis and high content immunocytochemistry image analysis. 

In this poster, you will explore:

  • How ioGlutamatergic Neurons carrying the TDP-43 M337V, MAPT N279K or MAPT P301S mutations were generated and characterised.
  • Development of high content image (HCI) analysis and droplet digital PCR assays to compare the TDP-43 M337V disease models and isogenic control.
  • MEA analysis showing a phenotype of reduced neuronal activity in the TDP-43 M337V homozygous disease model compared to the isogenic control.
  • Demonstration of a tau hyperphosphorylation phenotype in the MAPT P301S and N279K disease models by HCI analysis.

The data demonstrate the successful generation of relevant translational in vitro drug discovery models for ALS and FTD.

Oosterveen, et al

bit.bio & Charles River Laboratories

2023

Download resource

Related pages

News Read our latest updates and press coverage
Our platform Discover the cell identity coding platform behind our cells
Join us Explore the latest roles at bit.bio